I agree with you that the basket trial in cancer should be priority number #1, but I think the mono therapy pivotal trial should be #2. We know that mono therapy works, and it works very well, we just need to get the trial started and completed. Mono therapy will bring in big $.
GvHD is a low hanging fruit and CYDY needs to get after it. That’s my #3.
In regards to paying the note holder, I agree with cash instead of shares. But how much of a monthly burn would that be?